7-1-16 $CTIX ~ Cellceutix Corp. Due Diligence Report
$CTIX news
http://www.cellceutix.com/category/press-rele...r967e.dpbs
Latest PR's from Cellceutix:
30 June 2016 ~ Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
Read more http://cellceutix.com/cellceutix-corporation-...jfa0L.dpbs
15 June 2016 ~ Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis
Read more: http://cellceutix.com/cellceutix-starts-phase...obXUL.dpbs
Thurs, 9 June 2016 ~ Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
Read more: http://cellceutix.com/cellceutix-announces-di...-law-firm/
Mon, 6 June 2016 ~ Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Read more: http://cellceutix.com/cellceutix-announces-da...VH4MN.dpbs
Tues, 31 May 2016 ~ Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Read more: http://cellceutix.com/cellceutix-releases-pha...POUnq.dpbs
Thurs, 26 May 2016 ~ Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Read more: http://cellceutix.com/cellceutix-provides-add...SLmz0.dpbs
Tues, 24 May 2016 ~ Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Read more: http://cellceutix.com/cellceutix-phase-2-tria...-endpoint/
$CTIX filings - Perhaps the most important section
http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
$CTIX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA
Additional $CTIX company information:
## source: Cellceutix
Business Description: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
To find more information on completed and active Human Clinical Trials, please click the below link.
https://www.clinicaltrials.gov/ct2/results?te...rch=Search
$CTIX Share Structure
## source: otcmarkets.com
Market Value: $132,602,100 a/o Feb 09, 2016
Shares Outstanding: 118,500,536 a/o Oct 31, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001
Various $CTIX DD links
Cellceutix Corp. website - http://www.cellceutix.com
Company Email - info@cellceutix.com
Management - http://cellceutix.com/team/
Product Pipeline - http://cellceutix.com/pipeline/
Recent News and Press Releases - http://finance.yahoo.com/q/h?s=CTIX+Headlines
SEC Filings - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
Financials - http://www.otcmarkets.com/stock/CTIX/financials
Transfer Agent - http://www.westcoaststocktransfer.com/
Short Interest - http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics - http://www.finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster - http://www.finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Insider transactions - http://www.secform4.com/insider-trading/CTIX.htm
Income Statement - http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet - http://www.finance.yahoo.com/q/bs?s=CTIX
Cash Flow - http://www.finance.yahoo.com/q/cf?s=CTIX+Cash...amp;annual
Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?...pact=false
WIPO
http://www.wipo.int/patentscope/search/en/det...ing=FP src="/images/icons/icon_sad.gif" class="post_smiley" /> Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sec...amp;d=PG01
http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,796,275
Current/Completed Human Trials
http://www.clinicaltrials.gov/ct2/results?ter...rch=Search
1. Prurisol - Psoriasis (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT021...amp;rank=1
2. Prurisol - Psoriasis (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT024...amp;rank=2
3. Brilacidin - Oral Mucositis (Phase 2, Active, Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT023...amp;rank=3
4. Kevetrin - Solid Tumors (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=4
5. Brilacidin - ABSSSI (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT020...amp;rank=5
6. Brilacidin – ulcerative proctitis (Phase 2, Active, Recruiting)
$CTIX charts
$CTIX news
http://www.cellceutix.com/category/press-rele...r967e.dpbs
Latest PR's from Cellceutix:
30 June 2016 ~ Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
Read more http://cellceutix.com/cellceutix-corporation-...jfa0L.dpbs
15 June 2016 ~ Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis
Read more: http://cellceutix.com/cellceutix-starts-phase...obXUL.dpbs
Thurs, 9 June 2016 ~ Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
Read more: http://cellceutix.com/cellceutix-announces-di...-law-firm/
Mon, 6 June 2016 ~ Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Read more: http://cellceutix.com/cellceutix-announces-da...VH4MN.dpbs
Tues, 31 May 2016 ~ Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Read more: http://cellceutix.com/cellceutix-releases-pha...POUnq.dpbs
Thurs, 26 May 2016 ~ Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Read more: http://cellceutix.com/cellceutix-provides-add...SLmz0.dpbs
Tues, 24 May 2016 ~ Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Read more: http://cellceutix.com/cellceutix-phase-2-tria...-endpoint/
$CTIX filings - Perhaps the most important section
http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
$CTIX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA
Additional $CTIX company information:
## source: Cellceutix
Business Description: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
To find more information on completed and active Human Clinical Trials, please click the below link.
https://www.clinicaltrials.gov/ct2/results?te...rch=Search
$CTIX Share Structure
## source: otcmarkets.com
Market Value: $132,602,100 a/o Feb 09, 2016
Shares Outstanding: 118,500,536 a/o Oct 31, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001
Various $CTIX DD links
Cellceutix Corp. website - http://www.cellceutix.com
Company Email - info@cellceutix.com
Management - http://cellceutix.com/team/
Product Pipeline - http://cellceutix.com/pipeline/
Recent News and Press Releases - http://finance.yahoo.com/q/h?s=CTIX+Headlines
SEC Filings - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany
Financials - http://www.otcmarkets.com/stock/CTIX/financials
Transfer Agent - http://www.westcoaststocktransfer.com/
Short Interest - http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics - http://www.finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster - http://www.finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Insider transactions - http://www.secform4.com/insider-trading/CTIX.htm
Income Statement - http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet - http://www.finance.yahoo.com/q/bs?s=CTIX
Cash Flow - http://www.finance.yahoo.com/q/cf?s=CTIX+Cash...amp;annual
Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?...pact=false
WIPO
http://www.wipo.int/patentscope/search/en/det...ing=FP
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sec...amp;d=PG01
http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,796,275
Current/Completed Human Trials
http://www.clinicaltrials.gov/ct2/results?ter...rch=Search
1. Prurisol - Psoriasis (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT021...amp;rank=1
2. Prurisol - Psoriasis (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT024...amp;rank=2
3. Brilacidin - Oral Mucositis (Phase 2, Active, Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT023...amp;rank=3
4. Kevetrin - Solid Tumors (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT016...amp;rank=4
5. Brilacidin - ABSSSI (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT020...amp;rank=5
6. Brilacidin – ulcerative proctitis (Phase 2, Active, Recruiting)
$CTIX charts
2
1
